Literature DB >> 17047216

National surveillance of emergency department visits for outpatient adverse drug events.

Daniel S Budnitz1, Daniel A Pollock, Kelly N Weidenbach, Aaron B Mendelsohn, Thomas J Schroeder, Joseph L Annest.   

Abstract

CONTEXT: Adverse drug events are common and often preventable causes of medical injuries. However, timely, nationally representative information on outpatient adverse drug events is limited.
OBJECTIVE: To describe the frequency and characteristics of adverse drug events that lead to emergency department visits in the United States. DESIGN, SETTING, AND PARTICIPANTS: Active surveillance from January 1, 2004, through December 31, 2005, through the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project. MAIN OUTCOME MEASURES: National estimates of the numbers, population rates, and severity (measured by hospitalization) of individuals with adverse drug events treated in emergency departments.
RESULTS: Over the 2-year study period, 21,298 adverse drug event cases were reported, producing weighted annual estimates of 701,547 individuals (95% confidence interval [CI], 509,642-893,452) or 2.4 individuals per 1000 population (95% CI, 1.7-3.0) treated in emergency departments. Of these cases, 3487 individuals required hospitalization (annual estimate, 117,318 [16.7%]; 95% CI, 13.1%-20.3%). Adverse drug events accounted for 2.5% (95% CI, 2.0%-3.1%) of estimated emergency department visits for all unintentional injuries and 6.7% (95% CI, 4.7%-8.7%) of those leading to hospitalization and accounted for 0.6% of estimated emergency department visits for all causes. Individuals aged 65 years or older were more likely than younger individuals to sustain adverse drug events (annual estimate, 4.9 vs 2.0 per 1000; rate ratio [RR], 2.4; 95% CI, 1.8-3.0) and more likely to require hospitalization (annual estimate, 1.6 vs 0.23 per 1000; RR, 6.8; 95% CI, 4.3-9.2). Drugs for which regular outpatient monitoring is used to prevent acute toxicity accounted for 41.5% of estimated hospitalizations overall (1381 cases; 95% CI, 30.9%-52.1%) and 54.4% of estimated hospitalizations among individuals aged 65 years or older (829 cases; 95% CI, 45.0%-63.7%).
CONCLUSIONS: Adverse drug events among outpatients that lead to emergency department visits are an important cause of morbidity in the United States, particularly among individuals aged 65 years or older. Ongoing, population-based surveillance can help monitor these events and target prevention strategies.

Entities:  

Mesh:

Year:  2006        PMID: 17047216     DOI: 10.1001/jama.296.15.1858

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  245 in total

1.  CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.

Authors:  Karla I Claudio-Campos; Pablo González-Santiago; Jessica Y Renta; Jovaniel Rodríguez; Kelvin Carrasquillo; Andrea Gaedigk; Abiel Roche; Jorge Ducongé
Journal:  Pharmacogenomics       Date:  2018-12-06       Impact factor: 2.533

2.  Drug Hypersensitivity Reactions Documented in Electronic Health Records within a Large Health System.

Authors:  Adrian Wong; Diane L Seger; Kenneth H Lai; Foster R Goss; Kimberly G Blumenthal; Li Zhou
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-01

3.  Identification of inappropriate medication use in elderly patients with frequent emergency department visits.

Authors:  Jeffrey Wong; Patricia Marr; Debbie Kwan; Soumia Meiyappan; Lesley Adcock
Journal:  Can Pharm J (Ott)       Date:  2014-07

4.  Guided medication dosing for elderly emergency patients using real-time, computerized decision support.

Authors:  Richard T Griffey; Helen G Lo; Elisabeth Burdick; Carol Keohane; David W Bates
Journal:  J Am Med Inform Assoc       Date:  2011-11-03       Impact factor: 4.497

5.  Comprehensive medication review: development of a collaborative procedure.

Authors:  Saija Leikola; Lea Tuomainen; Sirpa Peura; Antti Laurikainen; Alan Lyles; Eeva Savela; Marja Airaksinen
Journal:  Int J Clin Pharm       Date:  2012-06-19

6.  Drug-eluting stents in the elderly.

Authors:  Samip Vasaiwala; Daniel E Forman; Laura Mauri
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-01

7.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

8.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

9.  Over-the-counter medication overuse and bowel obstruction.

Authors:  Benjamin Zaniello; Erica Phillips-Caesar
Journal:  J Am Geriatr Soc       Date:  2014-02       Impact factor: 5.562

10.  Cough and cold medication adverse events after market withdrawal and labeling revision.

Authors:  Lee M Hampton; Duc B Nguyen; Jonathan R Edwards; Daniel S Budnitz
Journal:  Pediatrics       Date:  2013-11-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.